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aptamer-hybrid nanoparticle bioconjugate 
efficiently delivers miRNA-29b to non-small-cell 
lung cancer cells and inhibits growth by 
downregulating essential oncoproteins
Maryna Perepelyuk
christina Maher
ashakumary 
lakshmikuttyamma
sunday a shoyele
Department of Pharmaceutical 
science, college of Pharmacy, Thomas 
Jefferson University, Philadelphia, 
Pa, Usa
Abstract: MicroRNAs (miRNAs) are potentially attractive candidates for cancer therapy. 
However, their therapeutic application is limited by lack of availability of an efficient delivery 
system to stably deliver these potent molecules intracellularly to cancer cells while avoiding 
healthy cells. We developed a novel aptamer-hybrid nanoparticle bioconjugate delivery system 
to selectively deliver miRNA-29b to MUC1-expressing cancer cells. Significant downregulation 
of oncoproteins DNMT3b and MCL1 was demonstrated by these MUC1 aptamer-functionalized 
hybrid nanoparticles in A549 cells. Furthermore, downregulation of these oncoproteins led to 
antiproliferative effect and induction of apoptosis in a superior version when compared with 
Lipofectamine 2000. This novel aptamer-hybrid nanoparticle bioconjugate delivery system 
could potentially serve as a platform for intracellular delivery of miRNAs to cancer cells, hence 
improving the therapeutic outcome of lung cancer.
Keywords: aptamer, nanoparticles, microRNA, lung cancer, targeted delivery
Introduction
Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer mortal-
ity in the US and the world, with a 5-year survival rate of only 15% for all stages 
combined.1,2 There has not been any significant decrease in the overall 5-year mortality 
rate for .4 decades despite the investment of billions of dollars into research.3 This 
could be attributed to lack of precise process of screening, heterogeneity of diseases, 
and, most importantly, the lack of novel therapies coming through.
MicroRNAs (miRNAs) are a novel RNA-interference technology that is currently 
being explored as a promising strategy in lung cancer treatment. They are small in 
size (~22 nucleotides), and they regulate gene expression at the post-transcription 
level through RNA interference. They may be seen as a new tool in the box for cancer 
treatment. Members of miRNA-29 family have been known to play an important role 
in cancer by regulating cell differentiation, proliferation, apoptosis, invasion, and 
migration.4,5 However, clinical application of this relatively novel therapeutic faces 
many challenges, including degradation in serum, rapid blood clearance, stimula-
tion of immune response, off-target effects, and poor cellular uptake.6 Recently, 
our group developed a novel targeted hybrid nanoparticle delivery system.7–9 This 
delivery system demonstrated its ability to protect loaded oligonucleotide against 
serum nuclease, reduce rate of blood clearance, efficient cellular uptake, and selective 
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delivery to lung cancer in a mouse model.7–9 This hybrid 
nanoparticle delivery system was able to achieve all the 
aforementioned abilities because of the uniqueness of its 
makeup. Our hybrid nanoparticle technology benefits from 
the incorporation of human immunoglobulin G (human IgG) 
and poloxamer-188 (polyoxyethylene–polyoxypropylene 
block copolymer), to achieve stable and efficient delivery 
of nucleic acid-based therapeutics.7 Human IgG is the 
main encapsulating component of these hybrid nanopar-
ticles. Human IgG antibody also helps to reduce/eliminate 
well-documented immunogenic reaction experienced with 
most nanoparticle formulations, by “deceiving” the body 
to believe that the nanoparticles are natural components of 
the blood.7 Poloxamer-188, a nonionic triblock copolymer, 
helps to circumvent the reticuloendothelial system during 
systemic circulation, since it has been previously used as a 
stealth polymer by preventing macrophage uptake during 
circulation.10,11
In the present study, we aim to optimize cellular uptake 
of miRNA-29b in lung cancer cells using our novel targeted 
hybrid nanoparticle system to selectively deliver miRNA-29b 
to lung cancer cells. Furthermore, we demonstrate the 
cancer-suppressing and apoptotic ability of encapsulated 
miRNA-29b in lung cancer cell lines (A549). We hypothesize 
that our novel targeted hybrid nanoparticles will efficiently 
deliver loaded miRNA-29b to lung cancer cells while 
avoiding normal cells by conjugation of mucin 1 (MUC1) 
aptamer to the nanoparticles. Furthermore, we hypothesize 
that selectively delivered miRNA-29b will downregulate 
oncoproteins myeloid cell leukemia sequence 1 (MCL1) 
and DNA methyltransferase 3B (DNMT3B) in lung cancer, 
hence inhibiting cancer cell growth.
miRNA-29b is the most abundantly expressed of all 
miRNA-29 families in normal cells.12 Previous studies have 
demonstrated that miRNA-29b plays an important role in 
cancer by regulating cell proliferation, differentiation, and 
apoptosis.5,6,13,14 It is usually silenced or downregulated in 
lung cancer and other types of cancer.6,15 In contrast, forced 
expression in acute myeloid leukemia and lung cancer 
resulted in significant reduction of DNMT3B at both pro-
tein and mRNA levels by direct interaction.15 Downregula-
tion of DNMT3B led to inhibition of cell proliferation and 
apoptosis of lung cancer cells.15,16 Furthermore, MCL1, 
a potent antiapoptotic protein of the BCL-2 family, has 
been shown to be downregulated by miRNA-29b in cancer 
cells.15 miRNA-29b is therefore a very attractive candidate 
for miRNA-based therapeutics due to its potent tumor sup-
pressant capabilities.
To actively and selectively deliver the encapsulated 
miRNA-29b to lung cancer cells, these nanoparticles were 
functionalized with MUC1 aptamer.
MUC1 is a transmembrane protein that is aberrantly 
overexpressed in NSCLCs.17 MUC1 has been shown to be 
overexpressed in .80% of lung adenocarcinoma.17 It has also 
been shown that targeting MUC1 function inhibits mutant 
K-ras signaling in NSCLC cells.17 We aim to take advantage 
of this overexpression in NSCLC to achieve an optimized 
targeting of miRNA-29b to NSCLC by conjugating MUC1 
aptamer to the surface of our hybrid nanoparticles.
Previous studies have shown that MUC1 aptamer-
functionalized nanoparticles improved the efficacy of drug 
delivery to breast cancer cells.18
Experimental section
Materials
Human IgG was purchased from Equitech-Bio Inc. 
(Kerrville, TX, USA). Poloxamer-188, RNase-free water, 
4,6-diamidino-2-phenylindole (DAPI), and fetal bovine 
serum (FBS) were obtained from Thermo Fisher Scientific 
(Waltham, MA, USA). Aptamer against MUC1 (5′-GCA 
GTT GAT CCT TTG GAT ACC CTG G-3′) was designed 
and purchased from GE Healthcare Bio-Sciences Corp. 
(Piscataway, NJ, USA). A C12 spacer was attached to the 
aptamer at the 3′-end to form the following sequence: 5′-GCA 
GTT GAT CCT TTG GAT ACC CTG G-C
12
H
25
-3′. One 
aptamer was modified with 3′-NH
2
 and 5′-FITC, whereas the 
other was only modified with 3′-NH
2
. The aptamers contained 
a 12-carbon spacer. siGLO-Green (6-FAM-labeled) was 
obtained from GE Healthcare Bio-Sciences Corp. HCl was 
obtained from Thermo Fisher Scientific. MiRIDIAN mimic 
with miR-29b and miRIDIAN mimic NC were obtained 
from GE Healthcare Bio-Sciences Corp. Pierce RIPA lysis 
buffer was purchased from Thermo Fisher Scientific. Rabbit 
antihuman DNMT3B and rabbit antihuman MCL1 anti-
body were obtained from Thermo Fisher Scientific. Mouse 
antihuman β-tubulin antibody was purchased from Sigma-
Aldrich (St Louis, MO, USA).
cell culture
Adenocarcinoma cell line A549 and normal lung fibro-
blast cell line MRC-5 were obtained from American Type 
Culture Collection (Rockville, MD, USA). A549 cell was 
originally derived from a 58-year-old male Caucasian, 
while MRC-5 was originally derived from a 14-week gesta-
tion male Caucasian. A549 cells were maintained in F12 K 
medium supplemented with 10% FBS and 1% antibiotics. 
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MRC-5 was maintained in Eagle’s Minimum Essential 
Medium supplemented with 10% FBS. Both cells were kept 
in a humidified air atmosphere with 5% carbon dioxide.
Preparation of nanoparticles
Human IgG was diluted in 0.01N HCl to make up IgG 
concentration of 1 mg/mL (ie, 10 mg) in 10 mL of 0.01 N 
HCl. A total of 0.73 mg of miRNA-29b was then added. 
The mixture was stirred on a magnetic stirrer until all the 
components were fully dissolved. The mixture was titrated 
with 0.01 N NaOH up to a pH value close to 7. Nanoparticles 
were spontaneously formed at the pH value very close to 7. 
The nanoparticles were allowed to mix on the magnetic stirrer 
for ~10 minutes. The colloidal suspension was centrifuged 
using a microcentrifuge (Eppendorf centrifuge 5418) at 
2,000 rpm for 5 minutes. The supernatant was either decanted 
or kept for the measurement of unencapsulated miRNA-29b 
to be used to calculate encapsulation efficiency and load-
ing capacity. Nanoparticles were then rinsed three times 
with double distilled deionized water. Nanoparticles were 
subsequently suspended in 0.2% v/v poloxamer-188, with 
gentle shaking for 10 minutes in order to coat nanoparticles 
with poloxamer-188. Nanoparticles were centrifuged and the 
supernatant decanted before being rinsed thrice with double 
distilled deionized water. Particles were then loaded into a 
freeze dryer (Labconco Freeze Zone 4.6), and lyophilization 
was performed for 48 hours.
conjugation of aptamer to prepared 
nanoparticles
A total of 50 µL of poloxamer-free nanoparticle suspension 
(10 µg/mL in DNase, RNase-free water) was mixed with 
100 µL of 40 mM EDC and 100 µL of 10 mM NHS for 
15 minutes at room temperature with gentle stirring. This 
helps to activate the carboxyl groups on nanoparticles for 
aptamer conjugation. A total of 50 µL of 1 µg/mL aptamer in 
DNase, RNAse-free water was then added to the nanoparticles 
and mixed gently for 2 hours at room temperature. Nanoparti-
cles were subsequently centrifuged at 4,000 rpm and 10°C for 
5 minutes using 30 kDa cutoff centrifugal ultrafilters (EMD 
Millipore, Billerica, MA, USA) to exclude unreacted EDC 
and NHS. Aptamer-functionalized nanoparticles were then 
suspended in 0.2% v/v poloxamer-188, with gentle shaking 
for 10 minutes in order to coat them with poloxamer-188.
characterization of nanoparticles
Particle size and surface charge (zeta potential) of the nanopar-
ticles were measured using photon correlation spectroscopy 
(ZetaSizer Nano ZS; Malvern Instruments, Malvern, UK). 
Nanoparticles were dispersed in deionized water followed 
by sonication for ~5 minutes. A scattering angle (θ ) of 
173° was used to measure intensity autocorrelation. The 
Z-average and polydispersity index were recorded in tripli-
cate. For zeta potential, samples were taken in a universal dip 
cell (Malvern Instruments) and the zeta potential recorded 
in triplicate.
We evaluated the shape of nanoparticles using scanning 
electron microscopy. Suspensions of nanoparticles were 
dropped on an aluminum stub and allowed to dry at room 
temperature. Samples were then coated with a thin layer of 
palladium. Coated samples were imaged using a Zeiss Supra 
50 V system (Carl Zeiss Meditec AG, Jena, Germany).
Fourier transform-infrared spectroscopy
A single-reflection-attenuated total reflectance with a dia-
mond internal reflection crystal installed in an iS10 FT-IR 
spectrometer (Thermo Fisher Scientific) was used to obtain 
spectra from different samples of nanoparticles. Lyophilized 
powders were placed on the surface of the attenuated total 
reflectance crystal after background spectra had been col-
lected. Spectra were collected after 64 scans at 4 cm-1 resolu-
tion. Data were analyzed using OMNIC software.
mirNa release study
Release of miRNA from MUC1 aptamer-functionalized 
hybrid nanoparticles was measured at pH values 5, 6.6, and 
7.4. Nanoparticles (3 mg) were dispersed in 0.5 mL of a 
buffered solution in a tubular cellulose dialysis membrane 
secured tightly at both ends. This was then incubated at 37°C 
in 5 mL buffered solution reservoirs while the reservoir was 
gently agitated. The amount of miRNA released at differ-
ent time points was analyzed and quantified for percentage 
cumulative release using ion-pair HPLC.
Ion-pair hPlc
miRNA was quantitatively determined using a Waters 
2695 separation module combined with a Waters 2998 
photodiode array detector Alliance HPLC system (Waters, 
Milford, MA, USA). Using a Clarity 3 µm Oligo-RP column 
(Phenomenex, Torrance, CA, USA) with a column dimension 
of 50×2.0 mm, 1 µL of miRNA sample was injected into 
the HPLC using 20 mM triethylamine–acetic acid (pH 7) 
and 5%–12% acetonitrile, gradient elusion as mobile phase. 
A flow rate of 0.2 mL/min was used for analysis. UV detec-
tion was performed at 269 nm, and Empower Pro software 
was used to record chromatograms.
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Fluorescence microscopy
A549 cells were seeded at a density of 2×104 in eight-well coated 
glass slides (Discovery Labware, Tewksbury, MA, USA) fol-
lowed by incubation for 48 hours. Cells were washed with PBS 
and incubated with either FITC-MUC1 aptamer-functionalized 
miRNA-29b-loaded hybrid nanoparticles or MUC1 aptamer-
functionalized siGLO-FAM-loaded hybrid nanoparticles dis-
persed in the Opti-Mem medium at a concentration of 100 µg/mL 
for 2 hours or 4 hours. Cells were then washed twice with 
PBS, fixed using 2% paraformaldehyde, and incubated at room 
temperature for 20 minutes. Cells washed with PBS were then 
blocked with 5% BSA for 30 minutes at room temperature. Cells 
were stained with either Lysotracker-Red or AlexaFluoro-555
-labeled wheat germ agglutinin (WGA-AF-555) before being 
stained with DAPI to visualize nucleus. Leica DMI 6000B fluo-
rescence microscope (Leica Microsystems, Wetzlar, Germany) 
was then used to observe cells after being mounted.
reverse transcriptase polymerase chain 
reaction
Qiagen RNAeasy kit (Qiagen, NV, Venlo, the Netherlands) 
was used to isolate total RNA and Verzo cDNA kit (Thermo 
Fisher Scientific) was used for reverse transcription. Poly-
merase chain reaction (PCR) was carried out in 25 µL reac-
tion mixtures. These reaction mixtures contained 1.0 µL of 
cDNA, 1× Qiagen buffer, 0.2 mM of dNTP mixture, 0.2 µM 
of each primer, and 1.5 U of HotStar Taq (Qiagen, Valencia, 
CA, USA). One cycle reaction at 95°C for 15 minutes was 
followed by 35 amplification cycles (94°C for 1 minute, 
66°C for 1 minute, and 72°C for 1 minute) for MUC1. For 
β-actin PCR, the same conditions except for the annealing 
temperature (59°C) were used. Primer sequences of MUC1 
are forward 5′-TCTCAAGCAGCCAGCGCCTGCCTG-3′, 
reverse 5′-TCCCCAGGTGGCAGCTGAACC-3′ and 
β-actin, forward 5′-CCAAGGCCAACCGCGAGAAGAT-3′, 
and reverse 5′-TTGCTCGAAGTCCAGGGCGA-3′.
Flow cytometry
Approximately 1 million cells per well (A549 and MRC-5) 
were seeded in a six-well plate and incubated for 48 hours. 
Cells were then treated with 100 µg/mL of siGLO-FAM-
loaded equivalent nanoparticles resuspended in Opti-MEM 
medium and incubated for 4 hours. Corresponding cells were 
pretreated with five times excess of free MUC1 aptamer, 
60 minutes prior to being treated with the MUC1 aptamer-
functionalized siGLO-FAM-loaded hybrid nanoparticles. 
Cells were washed with PBS. The cells were then detached 
by trypsinization and centrifuged at 1,000 rpm for 5 minutes. 
The pellet was washed and resuspended in PBS. A 0.75 µm 
cell strainer was used to filter the cells before being analyzed 
by flow cytometry (BDFACS caliber) to prevent cell aggre-
gates from blocking the tube lines of the instrument. A total 
of 10,000 cells were measured in each sample.
cell death detection elIsa
Cell death detection ELISA was carried out according to 
manufacturer’s instructions (Hoffman-La Roche Ltd., Basel, 
Switzerland). Briefly, A549 cells were seeded at a density 
of 2×104/well for 24 hours. Next day they were treated with 
MUC1 aptamer-functionalized miR-29b-loaded hybrid 
nanoparticles, MUC1 aptamer-functionalized negative con-
trol miRNA-loaded hybrid nanoparticles, and miR-29b in 
Lipofectamine 2000 Transfection Agent (Ambion, Austin, 
TX, USA) in Opti-MEM medium. Cells were washed in PBS 
and lysed in 200 µL/well of incubation buffer for 30 minutes 
at room temperature. The lysates were centrifuged at 
4,000× g for 10 minutes. Supernatant was used right away in 
the experiment. Plastic wells of the ELISA kit were incubated 
with coating solution (containing antihistone antibodies) 
overnight at 4°C. Next day it was substituted by incubation 
buffer for 30 minutes and washed three times with washing 
solution. A total of 100 µL of homogenate was placed into 
the wells and incubated for 90 minutes at room temperature 
with mild shaking. It was washed three times and incubated 
with conjugate solution containing anti-DNA peroxidase 
antibodies for 90 minutes. Wells were washed three times 
and exposed to ABTS substrate for 30 minutes until the color 
developed. Absorption values were read using a BioTek 
Epoch Microplate Spectrophotometer (BioTek Instruments 
Inc., Winooski, VT, USA) with Gen5 1.10 software.
Western blot analysis
One million A549 cells per well were seeded in culture dish 
and incubated for 48 hours. Cells were treated with MUC1 
aptamer-functionalized miR-29b-loaded hybrid nanoparticles 
(at an equivalent concentration of 100 nM of miRNA-29b), 
MUC1 aptamer-functionalized negative control miRNA-
loaded hybrid nanoparticles as well as miR-29b in Lipo-
fectamine 2000 reagent in Opti-MEM medium for 3 days. 
Cells were lysed in Pierce® RIPA buffer (Thermo Fisher 
Scientific) with addition of Pierce™ Protease Inhibitor Mini 
Tablets (Thermo Fisher Scientific) for 30 minutes on ice and 
centrifuged for 10 minutes at 10,000× g at +4°C. The protein 
concentration was determined with the Coomassie Plus™ 
(Bradford) Assay Kit (Thermo Fisher Scientific). A total of 
120 µg of total proteins was separated on NuPAGE 4%–12% 
Bis–Tris gels (Thermo Fisher Scientific) with NuPAGE 
MES SDS running buffer (Thermo Fisher Scientific) and 
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subsequently transferred onto a nitrocellulose membrane 
with a pore size of 0.22 µm (Thermo Fisher Scientific). The 
membrane with proteins was blocked according to manufac-
turer’s instructions (Thermo Fisher Scientific) for 1 hour at 
room temperature and probed with primary antibodies over-
night at 4°C DNMT3B (1:1,000, Thermo Fisher Scientific) 
and MCL1 (1:500; Thermo Fisher Scientific). β-Tubulin was 
used as a housekeeping gene (1:2,000, Sigma-Aldrich). Next 
day the membranes were washed three times for 5 minutes 
in wash buffer according to manufacturer’s instructions 
(Thermo Fisher Scientific) and incubated with secondary goat 
antimouse (Molecular Probes, Eugene, OR) or goat antirabbit 
(1:1,000, Thermo Fisher Scientific) secondary antibodies, con-
jugated with horseradish peroxidase at a dilution of 1:1,000.
Immune complexes were detected with chemiluminescent 
substrate, Pierce ECL Western Blotting substrate (Thermo 
Fisher Scientific), in a dark room on tabletop processor SRX-
101A (Konica Minolta, Tokyo, Japan).
cell viability
MTT assay was used to determine the effect of MUC1 
aptamer-functionalized miRNA-29b-loaded hybrid nanopar-
ticles on the proliferation of A549 cells. Cells (1×104) per 
well were seeded in 96-well plates and incubated at 37°C in a 
humidified atmosphere with 5% carbon dioxide for 24 hours. 
The cells were then treated with different concentrations of 
miRNA-29b-loaded hybrid nanoparticles in Opti-MEM for 
7 hours before being replaced with F12 K medium supple-
mented with 10% FBS and 1% antibiotics. This was then 
incubated for 72 hours. miRNA-29b transfected with NeoFX 
transfection agent was used as control in this experiment. 
Approximately 10 µL of 12 mmol/L MTT reagent was 
then added to each well. This was then incubated at 37°C 
for 4 hours. The medium was aspirated and 50 µL of sterile 
dimethyl sulfoxide was added to each well and mixed thor-
oughly with pipette. The cells were then incubated at 37°C 
for 10 minutes. The plate was read at 540 nm and 650 nm.
statistical analysis
Results are presented as mean ± SD, unless otherwise indi-
cated. Statistically significant difference between two groups 
was determined by two-tailed Student’s t-test. A P-value of 
0.05 was taken as statistically significant.
Results
Nanoparticle characterization
Particle size and zeta potential analysis by photon correlation 
spectroscopy, shown in Table 1, demonstrated that non-
functionalized hybrid nanoparticles were ~240 nm in size, 
while MUC1 aptamer-functionalized hybrid nanoparticles 
were ~595 nm in size. Nonfunctionalized hybrid nanopar-
ticles were negatively charged with a zeta potential of -2.1, 
while the conjugation of MUC1 aptamer increased the zeta 
potential of these nanoparticles to +4.1.
The schematic of the MUC1 aptamer-functionalized 
hybrid nanoparticle is shown in Figure 1A. Scanning electron 
micrograph in Figure 1B reveals that the hybrid nanoparticles 
were spherical in shape with smooth surface.
miRNA encapsulation efficiency (EE) and loading capac-
ity (LC) were measured using ion-pair HPLC analysis of the 
filtrates obtained by centrifuging the nanoparticles formed to 
determine the amount of unencapsulated miRNA-29b. EE 
and LC were calculated using the following equation:
 
%EE
A B
A
and %LC
A B
C
= × = − ×− 100 100,
 
(1)
where A = total amount of miRNA, B = free miRNA, and 
C = weight of hybrid nanoparticles in grams.
EE was calculated to be 98.8%±0.4%, whereas LC was 
calculated to be 8.6%±0.1%.
Conjugation of MUC1 aptamer to the surface of the nano-
particles was verified using fluorescence microscopy. Figure 1C 
demonstrates the successful conjugation of FITC-MUC1 
aptamer to the nanoparticles by the presence of fluorescent 
green color in the micrograph. In contrast, nonfunctionalized 
hybrid nanoparticles in Figure 1D showed the absence of 
fluorescent green color, confirming the lack of FITC-MUC1 
aptamer in the nanoparticles. We also used Fourier transform-
infrared (FT-IR) to confirm the successful conjugation of 
MUC1 aptamer to the nanoparticles. Figure 1E shows the FT-IR 
spectra generated from functionalized and nonfunctionalized 
hybrid nanoparticles. A distinctive and conspicuous difference 
between these sets of spectra bears testament to the successful 
conjugation of MUC1 aptamer to the hybrid nanoparticles.
In vitro release study
The release of miRNA-29b from MUC1 aptamer-functionalized 
hybrid nanoparticles was compared at pH values 5, 6.6, 
Table 1 Particle size and zeta potential of nonfunctionalized and 
aptamer-functionalized hybrid nanoparticles (mean ± sD, n=3)
Nanoparticle 
sample
Mean 
diameter  
(nm)
Polydispersity 
index
Zeta  
potential 
(mV)
Nonfunctionalized 
nanoparticles
236.2±35.1 0.242±0.007 -2.1±1.7
aptamer-functionalized 
nanoparticles
595.9±43.1 0.554±0.386 +4.1±1.0
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and 7.4. Figure 2 demonstrates a limitation in the release of 
miRNA-29b at pH values 6.6 and 7.4 when compared with 
the release profile at pH 5.
expression of MUc1 protein in Nsclc 
cells
Reverse transcriptase PCR was used to confirm the expres-
sion of MUC1 in two NSCLC cells, A549 and H460, to 
ensure that these cells actually express MUC1. Figure 3A 
demonstrates the relatively higher expression of MUC1 in 
both cancer cells when compared with normal lung fibroblast 
cell line MRC-5.
cellular uptake of MUc1 aptamer-
functionalized hybrid nanoparticles
Internalization of nanoparticles was evaluated using both 
flow cytometry and fluorescence microscopy. Flow cyto-
metry was used to compare nanoparticle uptake by A549 
and MRC-5. siGLO-FAM (green) was used as a model 
small double-stranded RNA labeled with FAM (a green 
dye). MUC1 aptamer conjugated to siGLO-loaded hybrid 
nanoparticles used in this experiment was bereft of FITC 
so as to avoid double fluorescence. As shown in Figure 3B, 
internalization of MUC1 aptamer-functionalized siGLO-
FAM-loaded nanoparticles in A549 cells was significantly 
Figure 1 hybrid nanoparticle characterization. 
Notes: (A) schematic of the aptamer-functionalized hybrid nanoparticle. (B) scanning electron micrograph of mirNa-loaded hybrid nanoparticles (scale bar: 500 nm). 
(C) Fluorescence micrograph of FITc-MUc1 aptamer-functionalized hybrid nanoparticles (scale bar: 25 µm). (D) Fluorescent micrograph of nonfunctionalized hybrid 
nanoparticles (scale bar: 25 µm). (E) FT-IR spectra of different nanoparticles to confirm the conjugation of aptamer to the nanoparticles.
Abbreviations: FT-Ir, Fourier transform-infrared; Igg, immunoglobulin g; mirNa, microrNa; MUc1, mucin 1.
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Fluorescence microscopy was used to study the interaction 
of FITC-MUC1 aptamer-functionalized hybrid nanoparticles 
with the cell membrane of A549 cells. Figure 4A demon-
strates the presence of FITC-MUC1 aptamer-functionalized 
hybrid nanoparticles (green color) on the cell membrane and 
inside the cytosol of A549 cells after 2 hours of incubation. 
Cell membrane of cells was stained with WGA-Alexa Fluor 
555 (red color) to enable the identification of the boundar-
ies of cells. Colocalization of both green and red colors on 
the membrane of the cells suggests a possible interaction 
between the FITC-MUC1 aptamer-functionalized hybrid 
nanoparticles and the membrane of the cells possibly due to 
the presence of MUC1 on the membrane.
Intracellular trafficking of internalized nanoparticles 
was also monitored using fluorescence microscopy. Late 
endosomes/lysosomes were labeled with LysoTracker-Red 
to enable the monitoring of the fate of internalized nanopar-
ticles. Figure 4B demonstrates maximum level of colocaliza-
tion of siGLO-FAM and LysoTracker-Red after 2 hours of 
incubation. However, after 4 hours, the siGLO-FAM was 
observed to be leaving the late endosomes and moving into 
the cytoplasm as indicated by the numerous green colored 
dots surrounding the nucleus.
Figure 2 In vitro release. 
Notes: Release profiles show that only a limited amount of microRNA-29b was 
released at pH values 6.6 and 7.4. However, an optimal release was observed at pH 5.
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using flow cytometry. **P#0.001, n=3.
Abbreviations: gaPDh, glyceraldehyde 3-phosphate dehydrogenase; MUc1, mucin 1.
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higher (P#0.001) in noninhibited cells when compared with 
cells pretreated with MUC1 aptamer. Furthermore, uptake 
of nanoparticles by MRC-5 was much lower than the uptake 
by A549 cells.
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MUC1 aptamer-functionalized miRNA-29b-
loaded hybrid nanoparticles downregulate 
DNMT3B and Mcl1 proteins and induce  
apoptosis in A549 cells
Figure 5A demonstrates the knockdown efficiency of MUC1 
aptamer-functionalized miRNA-29b-loaded nanoparticles 
against DNMT3B. These nanoparticles produced superior 
downregulation of DNMT3B when compared with Lipo-
fectamine 2000 transfected miRNA-29b and the negative 
control miRNA-loaded nanoparticles. Figure 5B further 
demonstrates the superior transfection efficiency of MUC1 
aptamer-functionalized miRNA-29b-loaded nanoparticles 
in comparison to lipofectamine by effectively downregu-
lating MCL1. In contrast, both lipofectamine and MUC1 
aptamer-functionalized negative control miRNA-loaded 
hybrid nanoparticles did not achieve the same level of 
downregulation.
Superior induction of apoptosis was observed in A549 
cells treated with MUC1 aptamer-functionalized miRNA-
29b-loaded hybrid nanoparticles when compared with 
nontreated cells, MUC1 aptamer-functionalized negative 
control miRNA-loaded hybrid nanoparticles-treated cells and 
lipofectamine-transfected miRNA-29b (Figure 5C).
Antiproliferative effect of MUC1 aptamer-functionalized 
miRNA-29b-loaded nanoparticles was evaluated using 
MTT assay and compared with that of NeoFX-transfected 
miRNA-29b and negative control miRNA-loaded nanopar-
ticles in A549 cells. As demonstrated in Figure 5D, MUC1 
aptamer-functionalized miRNA-29b-loaded nanoparticles 
were significantly more cytotoxic to A549 cells than NeoFX-
transfected miRNA-29b and negative control miRNA-loaded 
miRNA nanoparticles.
Discussion
Translational application of miRNA-based therapeutics is 
limited by a lack of smart nanoparticle delivery system to 
selectively deliver these important molecules intracellularly 
to cancer cells.
Recently, our group developed a novel hybrid nanopar-
ticles delivery system for safe and effective delivery of nucleic 
acid-based therapeutics to lung cancer.7–9 These nanoparticles 
were able to protect loaded nucleic acid against serum nuclease 
both in vitro and in vivo.7,9 Furthermore, these hybrid nanopar-
ticles were able to successfully deliver siRNA against mutant 
K-ras to the cytosol of A549 lung cancer cell lines without 
eliciting immunogenic/inflammatory response in murine 
macrophages, RAW 264.7.7,8 A significant downregulation of 
Figure 4 Fluorescence microscopy of nanoparticle–cell membrane interaction. 
Notes: (A) Micrographs showing the interaction between FITc-MUc1 aptamer-functionalized nanoparticles and cell membrane after 2-hour incubation. (B) Micrographs 
showing intracellular trafficking of internalized siGLO-FAM-loaded nanoparticles.
Abbreviations: DaPI, 4,6-diamidino-2-phenylindole; MUc1, mucin 1.
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both protein and mRNA of K-ras was achieved.7 In the present 
study, we were able to show that these nanoparticles could be 
functionalized with MUC1 aptamer to enable selective deliv-
ery of miRNAs to NSCLC cells. miRNA-29b was selected 
as a model miRNA since it has been previously reported 
that miRNA-29b, a tumor suppressor miRNA, is aberrantly 
expressed in NSCLC and its perturbation is related to tumor 
development and progression.4–6,19 Hence, miRNA-29b has 
been identified as an attractive candidate for miRNA-based 
therapeutics in NSCLC.
Hybrid nanoparticles comprising human IgG and 
poloxamer-188 were prepared using our previously reported 
isoelectric point (pI)-based nanoprecipitation technology.7,8,20 
This technology is based on the fact that proteins (human 
IgG) have minimum solubility but maximum precipitation 
at their pI. Nanoparticles produced using this technology 
are characteristically spherical in morphology as seen in 
Figure 1B. The particles were negatively charged possibly 
because of the presence of residual miRNA on the surface 
of the nanoparticles. However, the charge on the particles 
became positive following the conjugation of aptamer to 
the surface of the nanoparticles. The positive charge could 
be attributed to the presence of an amino group NH
2
 in the 
aptamer to facilitate the conjugation reaction. The loss of 
the lone pair of electrons on the amino group resulted in 
the positive charges. Both fluorescence microscopy and 
FT-IR analysis were performed to confirm the successful 
conjugation of MUC1 aptamer to the preformed hybrid 
nanoparticles. As shown in Figure 1C, FITC-labeled MUC1 
aptamer present on the surface of the hybrid nanoparticles 
led to the presence of green color in the MUC1 aptamer-
functionalized hybrid nanoparticles. In contrast, nonfunc-
tionalized hybrid nanoparticles did not show any green color 
in Figure 1D. This method of confirmation of successful 
aptamer conjugation to nanoparticles has been previously 
reported by Farokhzad et al.21 FT-IR data in Figure 1E 
demonstrate a distinctive difference between the spectra of 
MUC1 aptamer-functionalized hybrid nanoparticles and the 
Figure 5 Effect of miRNA-29b on essential oncoproteins in A549 cells. 
Notes: (A) Downregulation of DNMT3B by miRNA-29b nanoparticles. (B) Downregulation of MCL1 by miRNA-29b nanoparticles. miR-29b-nano represents MUC1 aptamer-
functionalized miRNA-29b-loaded hybrid nanoparticles: NC-nano represents MUC1 aptamer-functionalized negative control miRNA-loaded hybrid nanoparticles; miR-29b-
lipo represents lipofectamine 200-transfected miRNA-29b. (C) Cell death detection ELISA showing the induction of apoptosis in A549 cells (n=3). (D) antiproliferative effect 
of miRNA-29b nanoparticles in A549 cells (n=5).
Abbreviations: DaPI, 4,6-diamidino-2-phenylindole; mirNa, microrNa; MUc1, mucin 1.
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nonfunctionalized hybrid nanoparticles. Nonfunctionalized 
hybrid nanoparticles had a peak at 3,274 cm-1, which can 
be attributed to the group stretching vibration of both NH
2
 
and OH in the human IgG.22,23 Following the conjugation of 
MUC1 aptamer to the hybrid nanoparticles, this peak became 
sharper and more intense due to the presence of additional 
NH
2
 and OH stretching vibration attributable to the conjuga-
tion of NH
2
 aptamer to the hybrid nanoparticles. Both MUC1 
aptamer-functionalized and nonfunctionalized nanoparticles 
show a peak at ~1,541 cm-1, which could be attributed to the 
presence of amide II carbonyl stretch from human IgG in 
both nanoparticles.24 Furthermore, the peak at ~1,660 cm-1 
found in the spectra for MUC1 aptamer-functionalized hybrid 
nanoparticles but absent in the corresponding nonfunctional-
ized hybrid nanoparticles is attributed to conjugated amide 
stretching due to the conjugation of the amino group from the 
aptamer to the carboxyl groups present in human IgG.
Figure 2 demonstrates a limitation in the release of 
miRNA from MUC1 aptamer-functionalized hybrid nanopar-
ticles at pH values 6.6 and 7.4 when compared with the release 
profile at pH 5. This demonstrates the pH-sensitive nature of 
these nanoparticle delivery systems. At pH values of 6.6 and 
7.4, very limited amount of the loaded miRNA (,20%) was 
released throughout the study period. The limited release of 
siRNA at pH values 6.6 and 7.4 could be attributed to the 
reduced/limited solubility of human IgG at these pH values. 
Proteins are known to have limited solubility at pH values 
close to their pI.22 Since the pI of human IgG is 7, its solubility 
at neutral pH values is quite limited. This makes it difficult 
for the encapsulated miRNA to be released at this pH value, 
hence possibly limiting its release extracellularly in blood and 
tumor microenvironment. However, at acidic pH value of 5, 
an optimal miRNA release of ~100% was obtained due to the 
solubility of human IgG at this pH. An optimum release of the 
loaded miRNA is very desirable at pH 5, as pH 5 represents 
the acidic condition of endosome/lysosome.25,26
Uptake of MUC1 aptamer-functionalized nanoparticles, 
as demonstrated in Figure 3B, is significantly higher in 
A549 cells in comparison to MRC-5 cells. The differential 
internalization of nanoparticles between these cell lines could 
be attributed to the differential expression of MUC1 on the 
surface of these cells. While A549 is an adenocarcinoma cell 
line that is known to aberrantly overexpress MUC1,17 MRC-5 
is a normal lung fibroblast cell line with limited expression 
of MUC1 as shown in Figure 3A. To further confirm the 
involvement of MUC1 in the internalization of these nano-
particles, cells were pretreated with free MUC1 aptamer prior 
to their treatment with the MUC1 aptamer-functionalized 
hybrid nanoparticles to further elucidate the role of MUC1 
in uptake of nanoparticles. In Figure 3B, the significantly 
lower uptake of nanoparticles by A549 cells following pre-
treatment with free MUC1 aptamer could be attributed to 
competitive binding of this free MUC1 aptamer to MUC1 
on the membrane of the cells, limiting the uptake of MUC1 
aptamer-functionalized hybrid nanoparticles. Figure 4A 
further demonstrates the interaction between the cell mem-
brane of A549 cells and FITC-MUC1 aptamer conjugated 
to the hybrid nanoparticles. Presence of green color on the 
membrane of the A549 cells suggests the binding of these 
nanoparticles to the membrane prior to internalization.
One of the challenges facing the translational application 
of nanomedicine is the lack of effective endosomal escape 
following internalization by host cells. Stable nucleic acid 
lipid particles, which to date are the most advanced delivery 
system for nucleic acid, have demonstrated some limitation 
in recent studies. It was revealed that ~70% of the internal-
ized nucleic acid undergoes exocytosis (endocytic recycling) 
through egress of the lipid nanoparticles from late endosomes 
and lysosomes.27 It is therefore important to design nanopar-
ticle delivery system with the ability to escape the recycling 
pathways. To demonstrate the ability of our hybrid nanoparti-
cles to escape endocytic recycling, we monitored intracellular 
trafficking of internalized nanoparticles using fluorescence 
microscopy. In Figure 4B, colocalization of nanoparticles 
(green) and endosome (red) indicates the presence of nano-
particles in the late endosome after 2 hours of incubation.7 
However, release of siGLO-FAM (green) can be seen after 
4 hours of incubation, indicating the escape of encapsulated 
siGLO-FAM from late endosomes into the cytosol of the 
cells. This was possible due to the buffering capacity of the 
hybrid nanoparticles in the endosome. The solubility of IgG 
and poloxamer-188 at acidic pH 5, as demonstrated by the 
in vitro release data in Figure 2, makes it possible for the 
dissolved IgG in the endosome to activate the proton pump 
that raises osmotic pressure in the endosome subsequently 
leading to the swelling and subsequent escape of siGLO-
FAM from the endosomes into the cytoplasm.27,28
To evaluate the ability of internalized miRNA-29b to 
downregulate target oncoproteins DNMT3B and MCL1, 
expression of these proteins was monitored using Western blot. 
As demonstrated in Figure 5A and B, both target oncoproteins 
were downregulated in A549 cells following treatment with 
MUC1 aptamer-functionalized miRNA-29b-loaded hybrid 
nanoparticles in a superior version when compared with 
lipofectamine-transfected miRNA-29b. DNMT3B has been 
identified as a member of the DNA methyltransferase family 
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accounting for inactivation of tumor suppressor genes in 
many cancer cells.29 miRNA-29b has been reported to exert 
its tumor-suppressive role by directly targeting DNMT3b in 
cancer cells.5,6,29 Furthermore, miRNA-29b has been reported 
to be downregulated in malignant cells, whereas MCL1 was 
upregulated.5,6,30 MCL1 is a potent antiapoptic protein of the 
BCL-2 family. Downregulation of both DNMT3B and MCL1 
by miRNA-29b has been shown to inhibit cancer cell growth 
and promote apoptosis.29,30 However, the challenge facing the 
clinical application of miRNA-29b to cancer therapy is the 
availability of an efficient and safe delivery system to enhance 
intracellular delivery of this potent molecule to cancer cells. 
Figure 5A and B demonstrates the superior efficiency of MUC1 
aptamer-functionalized miRNA-29b-loaded hybrid nanopar-
ticles in downregulating oncoproteins DNMT3b and MCL1 
in NSCLC cells over lipofectamine-delivered miRNA-29b. 
The ability of this treatment modality to induce apoptosis in 
A549 cells due to downregulation of DNMT3B and MCL1 
was also demonstrated in Figure 5C. MUC1 aptamer miRNA-
29b-loaded hybrid nanoparticles also demonstrated superior 
antiproliferative effect in A549 cells in comparison to NeoFX-
delivered miRNA-29b. NeoFX is another commonly used, 
commercially available nucleic acid transfection agent.
Conclusion
MUC1 aptamer-functionalized hybrid nanoparticle delivery 
system was successfully fabricated. Our results demonstrated 
that this delivery system can efficiently deliver miRNAs 
effectively to cancer cells in a superior version compared 
with commercially available transfection agents. We also 
demonstrated that direct downregulation of DNMT3b and 
MCL1 led to antiproliferative effect in A549 cells. This novel 
aptamer-hybrid nanoparticle bioconjugate delivery system 
could potentially serve as a platform for intracellular delivery 
of miRNAs to cancer cells, hence improving the therapeutic 
outcome of lung cancer.
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